Literature DB >> 26836229

Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level in non-alcoholic steatohepatitis.

Hiroki Nishikawa1, Hirayuki Enomoto1, Yoshinori Iwata1, Kyohei Kishino1, Yoshihiro Shimono1, Kunihiro Hasegawa1, Chikage Nakano1, Ryo Takata1, Kazunori Yoh1, Takashi Nishimura1, Nobuhiro Aizawa1, Yoshiyuki Sakai1, Naoto Ikeda1, Tomoyuki Takashima1, Akio Ishii1, Hiroko Iijima1, Hideji Nakamura2, Shuhei Nishiguchi1.   

Abstract

AIM: To examine the relationship between the Wisteria floribunda agglutinin positive Mac-2-binding protein (WFA+ -M2BP) level and histological findings for patients with non-alcoholic steatohepatitis (NASH).
METHODS: A total of 134 NASH patients (mean age, 51.7 years) were analyzed. We examined the effect of WFA+ -M2BP level on severity of liver fibrosis comparing with other laboratory markers, including aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio, AST to platelet ratio index (APRI), FIB-4 index, platelet count and hyaluronic acid as serum liver fibrosis markers. Receiver-operator curve (ROC) analysis was performed for calculating the area under the ROC (AUROC).
RESULTS: The WFA+ -M2B P-value ranged from 0.2 cut-off index (COI) to 9.6 COI (median, 0.9). The median values in each fibrosis stage were: 0.7 COI in F1, 0.7 COI in F2, 1.2 COI in F3 and 2.4 COI in F4 (P < 0.001). For predicting liver cirrhosis (F4), WFA+ -M2BP level had the AUROC of 0.854 (sensitivity, 69.2%; specificity, 88.4%) and for predicting advanced liver fibrosis (≥F3), WFA+ -M2BP level yielded the second highest AUROC with a level of 0.842 (sensitivity, 73.7%; specificity, 80.2%) and for predicting significant liver fibrosis (≥F2), WFA+ -M2BP level yielded the highest AUROC with a level of 0.663 (sensitivity, 47.2%; specificity, 78.6%) among six liver fibrosis markers. The median values in patients with ballooning scores 1 (n = 58) and 2 (n = 76) were 0.6 and 1.1 COI, respectively (P < 0.001).
CONCLUSION: Serum WFA+ -M2BP level can be useful for assessing liver histological findings in patients with NASH.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  Wisteria floribunda agglutinin-positive Mac-2-binding protein; liver fibrosis; non-alcoholic steatohepatitis; predictability; serum marker

Year:  2016        PMID: 26836229     DOI: 10.1111/hepr.12662

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  15 in total

Review 1.  Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.

Authors:  Ken Shirabe; Yuki Bekki; Dolgormaa Gantumur; Kenichiro Araki; Norihiro Ishii; Atsushi Kuno; Hisashi Narimatsu; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2018-01-09       Impact factor: 7.527

2.  Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.

Authors:  Kazunori Kawaguchi; Masao Honda; Hajime Ohta; Takeshi Terashima; Tetsuro Shimakami; Kuniaki Arai; Taro Yamashita; Yoshio Sakai; Tatsuya Yamashita; Eishiro Mizukoshi; Takuya Komura; Masashi Unoura; Shuichi Kaneko
Journal:  J Gastroenterol       Date:  2017-08-28       Impact factor: 7.527

3.  Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.

Authors:  Masataka Kanno; Kazunori Kawaguchi; Masao Honda; Rika Horii; Hajime Takatori; Tetsuro Shimakami; Kazuya Kitamura; Kuniaki Arai; Taro Yamashita; Yoshio Sakai; Tatsuya Yamashita; Eishiro Mizukoshi; Shuichi Kaneko
Journal:  J Gastroenterol       Date:  2019-02-01       Impact factor: 7.527

4.  Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in non-alcoholic fatty liver disease.

Authors:  Lee-Lee Lai; Wah-Kheong Chan; Pavai Sthaneshwar; Nik Raihan Nik Mustapha; Khean-Lee Goh; Sanjiv Mahadeva
Journal:  PLoS One       Date:  2017-04-03       Impact factor: 3.240

Review 5.  Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods.

Authors:  Masato Yoneda; Kento Imajo; Hirokazu Takahashi; Yuji Ogawa; Yuichiro Eguchi; Yoshio Sumida; Masashi Yoneda; Miwa Kawanaka; Satoru Saito; Katsutoshi Tokushige; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2017-11-24       Impact factor: 7.527

6.  M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.

Authors:  Shereen A Saleh; Mohamed M Salama; Marwan M Alhusseini; Ghada A Mohamed
Journal:  World J Gastroenterol       Date:  2020-06-07       Impact factor: 5.742

Review 7.  Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Rohit Loomba; Namiki Izumi
Journal:  Ann Lab Med       Date:  2020-08-25       Impact factor: 3.464

8.  Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis.

Authors:  Kunihiro Hasegawa; Ryo Takata; Hiroki Nishikawa; Hirayuki Enomoto; Akio Ishii; Yoshinori Iwata; Yuho Miyamoto; Noriko Ishii; Yukihisa Yuri; Chikage Nakano; Takashi Nishimura; Kazunori Yoh; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Int J Mol Sci       Date:  2016-09-12       Impact factor: 5.923

9.  Speculation of the Time-Dependent Change of FIB4 Index in Patients with Nonalcoholic Fatty Liver Disease: A Retrospective Study.

Authors:  Hiroshi Miyata; Satoru Miyata
Journal:  Can J Gastroenterol Hepatol       Date:  2018-03-12

Review 10.  The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.

Authors:  Hideki Fujii; Norifumi Kawada
Journal:  Int J Mol Sci       Date:  2020-05-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.